Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. META
4. DPZ
5. IBM
6. CNC
7. KFY
8. SPY
9. MU
10. ENRD

Go back to Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
(NASDAQ: ACRS) Delayed: 4.84 --0 (-0%)
Previous Close $4.84    52 Week High $33.88 
Open $4.84    52 Week Low $14.12 
Day High $4.84    P/E N/A 
Day Low $4.84    EPS $0.00 
Volume 2,218